Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine

Olga Grinberg, Aharon Gedanken, Debabrata Mukhopadhyay, Chitta Ranjan Patra

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Inhibition of the EGFR signaling pathway is one of the attractive therapeutic targets for pancreatic cancer as recent studies demonstrated that EGFR is over-expressed in pancreatic cancer. In this article we have demonstrated the design of targeted drug delivery system containing Bovine Serum Albumin (BSA) microspheres as delivery vehicle, gemcitabine as anticancer drug and anti-EGFR (epidermal growth factor receptor) monoclonal antibody as targeting agent. The conjugated BSA microspheres were characterized by several physico-chemical techniques such as scanning electron microscope, optical microscopy, fluorescent microscopy etc. Administration of these BSA microspheres containing gemcitabine and anti-EGFR (BSA-Gem-EGFR) shows significant inhibition of pancreatic cancer cells (AsPC1) compared to the cells treated with only BSA microspheres, BSA with gemcitabine (BSA-Gem), and free gemcitabine. This strategy could be used as a generalized approach for the treatment of pancreatic cancer along with other cancers which overexpress EGFR on cell surface.

Original languageEnglish (US)
Pages (from-to)294-299
Number of pages6
JournalPolymers for Advanced Technologies
Issue number3
StatePublished - Mar 2013


  • Anti-EGFR monoclonal antibody
  • BSA microspheres
  • Gemcitabine
  • Pancreatic cancer cells (AsPC1)
  • Sonochemistry
  • Targeted drug delivery

ASJC Scopus subject areas

  • Polymers and Plastics


Dive into the research topics of 'Antibody modified Bovine Serum Albumin microspheres for targeted delivery of anticancer agent Gemcitabine'. Together they form a unique fingerprint.

Cite this